BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//ideon - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:ideon
X-ORIGINAL-URL:https://ideon.se
X-WR-CALDESC:Events for ideon
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240305T140000
DTEND;TZID=Europe/Stockholm:20240305T180000
DTSTAMP:20260315T185110
CREATED:20240118T114549Z
LAST-MODIFIED:20240718T214337Z
UID:374624-1709647200-1709661600@ideon.se
SUMMARY:WOMEN IN CLINICAL TRIALS
DESCRIPTION:Medicon Valley Alliance invites you to join this network meeting on Women in clinical trials\nWomen are underrepresented in clinical studies – especially in phase I trials were only 29 – 34 % of participants in Phase I trials are female. And 74 % of clinical trials do not report outcome by sex. But why is that?Is the reason for fewer women in clinical research mainly because researchers worry about the costs and legal issues if a participant gets pregnant? Also\, does it seem like including women in studies brings extra expenses for sponsors because they might react differently to the new drugs\, and age-related differences make things more complex? Does the tradition of leaving out certain groups affect how many women join clinical trials? And how do new rules about representation impact getting more women involved?Even though involving more women in trials can be more expensive and trickier for sponsors\, it’s important. This helps us really understand how drugs work. If a drug has more problems or doesn’t work well in women\, it can be even more expensive to take it off the market later. Including more women in studies gives us a better picture of how drugs work and how different groups might react to them.In this meeting we will hear from different experts\, that will enlighten us on the EU regulatory perspective\, the costs of including women\, and on how to recruit more women. \nSIGN UP»
URL:https://ideon.se/event/women-in-clinical-trials/
LOCATION:Medicon Village\, Inspira\, Scheelevägen 4\, Lund\, 223 63\, Sweden
ATTACH;FMTTYPE=image/jpeg:https://ideon.se/wp-content/uploads/2024/07/240305-womenshealth-network-banner-1080.jpg
END:VEVENT
END:VCALENDAR